Safety and immunogenicity of anti PD-L1 (atezolizumab) given as an immune primer or concurrently with extended field chemoradiotherapy for node positive locally advanced cervical cancer: An NRG oncology trial Meeting Abstract

  

Authors:	Mayadev, J.; Zamarin, D.; Deng, W.; Lankes, H.; Pesci, G.; Park, K.; Banbury, B.; Sherry, N.; Ghamande, S.; Holman, L.; Mathews, C.; O'Cearbhaill, R.; Aghajanian, C.; Schilder, R.
Abstract Title:	Safety and immunogenicity of anti PD-L1 (atezolizumab) given as an immune primer or concurrently with extended field chemoradiotherapy for node positive locally advanced cervical cancer: An NRG oncology trial
Meeting Title:	2022 Society of Gynecologic Oncology Annual Meeting
Journal Title:	Gynecologic Oncology
Volume:	166
Issue:	Suppl. 1
Meeting Dates:	2022 Mar 18-21
Meeting Location:	Phoenix, AZ
ISSN:	0090-8258
Publisher:	Elsevier Inc.
Date Published:	2022-08-01
Start Page:	S18
End Page:	S19
Language:	English
ACCESSION:	WOS:000892325300026
PROVIDER:	wos
DOI:	10.1016/S0090-8258(22)01242-2
Notes:	Meeting Abstract: 024 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/203087